Hims & Hers Stocks Rise After Workforce Cut Amid Regulatory Changes

Hims & Hers Health (NYSE: HIMS) experienced an 8% stock surge on Friday, May 30th, after announcing a 4% reduction in its workforce. This decision follows a U.S. ban, effective May 22nd, on producing generic versions of the weight-loss drug Wegovy. In response to this regulatory hurdle, HIMS partnered with Novo Nordisk to provide discounted Wegovy on its platform. Remarkably, HIMS has seen a 125% increase in stock value year-to-date.

Valuation Concerns

Given its current price of approximately $57, investors are questioning whether HIMS stock remains a worthwhile buy. Although the evaluation seems steep, the company’s strong financial performance justifies its high valuation. Nevertheless, the current price may pose challenges for new investors. There are few immediate concerns with HIMS stock, but it shows increased sensitivity to negative news or market fluctuations.

Comprehensive Financial Analysis

A thorough comparison of HIMS’s current valuation and recent operational results suggests strong growth, profitability, financial stability, and resilience. This analysis shows HIMS’s robust operational performance and overall financial health. For lower volatility investment options, the Trefis High Quality portfolio has surpassed the S&P 500, yielding over 91% returns since its inception.

Lofty Valuations Explained

The stock is considered expensive, trading at 6.6 times its sales, significantly higher than the S&P 500’s 3.0 ratio. HIMS’s price-to-earnings ratio stands at 72.1, nearly three times the market’s 26.4. Additionally, it commands 35.5 times its free cash flow, compared to the broader market’s 20.5. What supports these high valuations is HIMS’ remarkable growth trajectory.

Exceptional Growth Performance

HIMS has increased its revenues by an average of 78% over the past three years, while the S&P 500 only achieved 5.5%. Recently, revenues spiked by 86% to $1.5 billion in the last year, with the latest quarter reporting a remarkable 111% increase to $481 million.

Profitability Analysis

Despite impressive revenue growth, HIMS’s profitability is more modest. Its operating margin is 6.2%, below the S&P 500’s 13.2%. However, the operating cash flow margin is 18.7%, exceeding the market average of 14.9%. The net income margin stands at 9.2%, slightly less than the market’s 11.6%.

Strong Financial Position

HIMS maintains a robust financial status with only $63 million in debt against a market value of $13 billion, giving it a debt-to-equity ratio of just 0.5%, compared to the S&P 500’s 19.9%. The company holds substantial cash reserves, representing 36.2% of total assets compared to 13.8% for the broader market.

Investment Outlook

Investing in HIMS poses both opportunities and risks. The company showcases significant growth and financial stability, coupled with moderate profitability and volatility. While the fundamentals are strong, the high valuation limits growth potential. Investors interested in HIMS need to be ready for potential price volatility. For context, during the 2022 inflation crisis, HIMS stock fell 87.3% from its peak, far more than the S&P 500’s 25.4% decline. However, it fully recovered by June 2024, reaching a high of $68.74 in February 2025.

Currently, HIMS stock reflects optimistic expectations for sustained growth. If the company can continue expanding while improving profitability, the high valuation might be warranted. However, any slip in growth or negative market conditions could lead to significant price corrections.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.